Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2018-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2018年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '华兰生物工程股份有限公司 2018 年半年度报告摘要' which translates to 'Hualan Biological Engineering Co., Ltd. 2018 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and net assets for the half-year period of 2018. It also discusses operational highlights, shareholder information, and changes in consolidated entities. The document is a comprehensive financial report for a period shorter than a full fiscal year (half-year). The length is 3889 characters, which is typical for a summary but it contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-26 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's related party fund occupation and external guarantees. It references regulatory notices and compliance with rules but does not contain financial statements or detailed audit results. The document length is short (618 characters) and it is a formal opinion rather than a full audit report or annual report. It fits the category of Audit Report / Information (AR) as it is a standalone audit-related statement about compliance and internal checks, not a full annual report or other category. H1 2018
2018-08-26 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "华兰生物工程股份有限公司 2018 年半年度报告全文" which translates to "Hualan Biological Engineering Co., Ltd. 2018 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes financial figures for the first half of 2018, business segments, product descriptions, and management commentary. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2018
2018-08-26 Chinese
2018年1-6月财务报表（未经审计）
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report from 华兰生物工程股份有限公司 covering the period January to June 2018. It includes consolidated balance sheets, profit and loss statements, cash flow statements, and shareholders' equity changes, all with detailed notes and accounting figures. The presence of comprehensive financial statements and notes for a half-year period indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-26 Chinese
关于参股公司单克隆抗体药物研发进展的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (779 characters) about the acceptance of a clinical research application for a monoclonal antibody drug by the National Medical Products Administration (国家药品监督管理局). It includes risk warnings and states that the acceptance does not impact recent performance. There are no financial statements, no detailed financial data, no management discussion, or earnings information. The document is an official announcement regarding a regulatory milestone related to drug development, not a financial report or detailed management report. It fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about clinical trial application acceptance and related risk disclosures, which do not fit other specific categories.
2018-07-16 Chinese
关于实际控制人增持公司股份计划实施完成的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholding increase plan by the company's actual controller and chairman. It details the number of shares increased, the purpose, legal compliance, and the final shareholding percentages. There are no financial statements or detailed financial performance data. The document is a formal disclosure of a change in major shareholding levels, consistent with notifications about significant share ownership changes crossing thresholds.
2018-06-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.